Equities analysts expect that XOMA Corp (NASDAQ:XOMA) will post $740,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for XOMA’s earnings. The highest sales estimate is $1.22 million and the lowest is $260,000.00. XOMA posted sales of $900,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 17.8%. The company is expected to issue its next quarterly earnings results on Wednesday, November 6th.
On average, analysts expect that XOMA will report full-year sales of $10.59 million for the current financial year, with estimates ranging from $9.68 million to $11.50 million. For the next year, analysts expect that the business will post sales of $5.20 million, with estimates ranging from $1.80 million to $8.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for XOMA.
XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. The business had revenue of $0.96 million during the quarter, compared to analyst estimates of $0.63 million. XOMA had a negative net margin of 72.20% and a negative return on equity of 51.91%.
Shares of NASDAQ XOMA traded down $0.22 during trading on Friday, reaching $16.47. 51,996 shares of the company traded hands, compared to its average volume of 63,860. The firm’s 50 day moving average price is $17.10. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.90 and a quick ratio of 3.90. The stock has a market capitalization of $151.29 million, a PE ratio of -10.36 and a beta of 1.29. XOMA has a 52-week low of $11.02 and a 52-week high of $20.29.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Smart Portfolios LLC bought a new stake in XOMA in the first quarter worth $36,000. Athanor Capital LP purchased a new position in XOMA during the second quarter worth $149,000. California Public Employees Retirement System boosted its stake in XOMA by 11.5% during the fourth quarter. California Public Employees Retirement System now owns 11,860 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,220 shares during the period. First Manhattan Co. boosted its stake in XOMA by 100.0% during the first quarter. First Manhattan Co. now owns 20,000 shares of the biotechnology company’s stock worth $247,000 after buying an additional 10,000 shares during the period. Finally, Morgan Stanley boosted its stake in XOMA by 2,151.6% during the second quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after buying an additional 22,828 shares during the period. 47.63% of the stock is currently owned by institutional investors.
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
See Also: Day Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.